Fig. 4
The effect of MCS on type 2 diabetes patients with NAFLD model rat. a content of serum FBG and FINS, b level of serum TG and TC, c activities of serum ALT, AST and GGT
Fig. 4 | BMC Pharmacology and Toxicology
The effect of MCS on type 2 diabetes patients with NAFLD model rat. a content of serum FBG and FINS, b level of serum TG and TC, c activities of serum ALT, AST and GGT